Table 1 Cohort characterization.

From: Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

   

Immunophenotype

  

Total

Thymic

Mature

Early

  

230

107

43

60

Age (years)

    
 

≤55

219 (95%)

105 (98%)

40 (93%)

56 (93%)

 

>55

11 (5%)

2 (2%)

3 (7%)

4 (7%)

Sex

     
 

Female

64 (28%)

33 (31%)

9 (21%)

18 (30%)

 

Male

166 (72%)

74 (69%)

34 (79%)

42 (70%)

ETP

     
 

Yes

21 (10%)

0 (0%)

2 (5%)

19 (32%)

 

No

189 (90%)

107 (100%)

41 (95%)

41 (68%)

Methylation cluster

    
 

M1

25 (11%)

7 (7%)

10 (23%)

8 (13%)

 

M2

20 (9%)

12 (11%)

8 (19%)

0 (0%)

 

M3

25 (11%)

20 (19%)

3 (7%)

1 (2%)

 

M4

12 (5%)

10 (9%)

1 (2%)

1 (2%)

Molecular subgroup

    
 

LMO1

15 (7%)

9 (8%)

6 (14%)

0 (0%)

 

TLX3

26 (11%)

10 (9%)

6 (14%)

7 (12%)

 

TLX1

44 (19%)

42 (39%)

0 (0%)

0 (0%)

 

LYL1LMO2

32 (14%)

3 (3%)

10 (23%)

15 (25%)

 

HOXA

50 (22%)

19 (18%)

4 (9%)

23 (38%)

 

TAL1LMO

30 (13%)

17 (16%)

9 (21%)

2 (3%)

 

HOXA13

7 (3%)

0 (0%)

1 (2%)

6 (10%)

 

NKX2

4 (2%)

3 (3%)

1 (2%)

0 (0%)

 

TAL2

1 (0%)

0 (0%)

0 (0%)

0 (0%)

  1. The table shows the frequencies for age, sex, ETP status, molecular subgroup, and methylation cluster in the overall cohort and according to their immunophenotype. Immunophenotype is known for 210 out of the 230 T-ALL patients.
Back to article page